Dupilumab is a human monoclonal antibody that targets and inhibits two key proteins involved in the inflammatory process in AD: interleukin-4 (IL-4) and interleukin-13 (IL-13). Dupilumab is directed against the shared alpha subunit of the interleukin-4 receptors that blocks signaling from both interleukin-4 and interleukin-13, showing efficacy in patients with moderate to severe asthma and elevated eosinophil levels [2]. Here, IL13 is linked to asthma.